Patents by Inventor Danxi Li

Danxi Li has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20080241131
    Abstract: Human SPHK genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of SPHK are provided.
    Type: Application
    Filed: April 3, 2008
    Publication date: October 2, 2008
    Applicant: Exelixis Inc.
    Inventors: Lori S. Friedman, Gregory D. Plowman, Michael R. Costa, Danxi Li, Roel P. Funke, Tak Hung
  • Publication number: 20080166709
    Abstract: Human MARK genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of MARK are provided.
    Type: Application
    Filed: January 28, 2007
    Publication date: July 10, 2008
    Applicant: EXELIXIS, INC.
    Inventors: Lori Friedman, Gregory D. Plowman, Marcia Belvin, Helen Francis-Lang, Danxi Li, Roel P. Funke, Mario N. Lioubin
  • Publication number: 20070160539
    Abstract: Human hPRP4 genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of hPRP4 are provided.
    Type: Application
    Filed: January 26, 2007
    Publication date: July 12, 2007
    Applicant: EXELIXIS, INC.
    Inventors: Lori Friedman, Gregory Plowman, Tak Hung, Helen Francis-Lang, Danxi Li, Roel Funke, Michael Costa
  • Publication number: 20070134732
    Abstract: Human LCE genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of LCE are provided.
    Type: Application
    Filed: June 3, 2002
    Publication date: June 14, 2007
    Inventors: Marcia Belvin, Helen Francis-Lang, Danxi Li, Roel Funke
  • Publication number: 20060252035
    Abstract: Human SPHK genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of SPHK are provided.
    Type: Application
    Filed: August 2, 2002
    Publication date: November 9, 2006
    Inventors: Lori Friedman, Gregory Plowman, Michael Costa, Danxi Li, Roel Funke, Tak Hung
  • Publication number: 20060160764
    Abstract: Human LIMK genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of LIMK are provided.
    Type: Application
    Filed: March 17, 2006
    Publication date: July 20, 2006
    Applicant: Exelixis, Inc.
    Inventors: Lori Friedman, Gregory Plowman, Marcia Belvin, Helen Francis-Lang, Danxi Li, Roel Funke
  • Publication number: 20060121041
    Abstract: Human GPC genes are identified as modulators of the IRRTK or p21 pathways, and thus are therapeutic targets for disorders associated with defective IRRTK or p21 function. Methods for identifying modulators of IRRTK or p21, comprising screening for agents that modulate the activity of GPC are provided.
    Type: Application
    Filed: July 10, 2002
    Publication date: June 8, 2006
    Inventors: Lori Friedman, Gregory Plowman, Tom Kidd, Roel Funke, Danxi Li, Siobhan Roche
  • Publication number: 20060121457
    Abstract: Human GFAT genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of GFAT are provided.
    Type: Application
    Filed: June 2, 2002
    Publication date: June 8, 2006
    Inventors: Lori Friedman, Gregory Plowman, Marcia Belvin, Helen Francis-Lang, Danxi Li, Roel Funke
  • Patent number: 7049088
    Abstract: Human PRMT genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of PRMT are provided.
    Type: Grant
    Filed: June 5, 2002
    Date of Patent: May 23, 2006
    Assignee: Exelixis, INC
    Inventors: Lori Friedman, Gregory D. Plowman, Marcia Belvin, Helen Francis-Lang, Danxi Li, Roel P. Funke, Rolf Peter Ryseck, Lata Jayaraman, David K. Bol, Matthew Lorenzi
  • Publication number: 20060024665
    Abstract: Human PRMT genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of PRMT are provided.
    Type: Application
    Filed: September 30, 2005
    Publication date: February 2, 2006
    Inventors: Lori Friedman, Gregory Plowman, Marcia Belvin, Helen Francis-Lang, Danxi Li, Roel Funke, Rolf Ryseck, Lata Jayaraman, David Bol, Matthew Lorenzi
  • Publication number: 20060024673
    Abstract: Human SLC2A genes are identified as modulators of the p53 pathway, and thus as therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of SLC2A are provided.
    Type: Application
    Filed: June 3, 2002
    Publication date: February 2, 2006
    Inventors: Lori Friedman, Gregory Plowman, Marcia Belvin, Helen Francis-Lang, Danxi Li, Roel Funke
  • Publication number: 20050227228
    Abstract: Human MAP3K genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of MAP3K are provided.
    Type: Application
    Filed: June 3, 2002
    Publication date: October 13, 2005
    Inventors: Lori Friedman, Gregory Plowman, Marcia Belvin, Helen Francis-Lang, Danxi Li, Roel Funke
  • Publication number: 20050186200
    Abstract: Human HADH genes are identified as modulators of the p21 pathway, and thus are therapeutic targets for disorders associated with defective p21 function. Methods for identifying modulators of p21, comprising screening for agents that modulate the activity of HADH are provided.
    Type: Application
    Filed: April 11, 2005
    Publication date: August 25, 2005
    Inventors: Lori Friedman, Gregory Plowman, Roel Funke, Marcia Belvin, Danxi Li, Stephanie Robertson
  • Publication number: 20050186566
    Abstract: Human PRMT genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of PRMT are provided.
    Type: Application
    Filed: June 5, 2002
    Publication date: August 25, 2005
    Inventors: Lori Friedman, Gregory Plowman, Marcia Belvin, Helen Francis-Lang, Danxi Li, Roel Funke, Rolf Ryseck, Lata Jayaraman, David Bol, Matthew Lorenzi
  • Publication number: 20050181481
    Abstract: Human HADH genes are identified as modulators of the p21 pathway, and thus are therapeutic targets for disorders associated with defective p21 function. Methods for identifying modulators of p21, comprising screening for agents that modulate the activity of HADH are provided.
    Type: Application
    Filed: April 11, 2005
    Publication date: August 18, 2005
    Inventors: Lori Friedman, Gregory Plowman, Roel Funke, Marcia Belvin, Danxi Li, Stephanie Robertson
  • Patent number: 6927022
    Abstract: Human HADH genes are identified as modulators of the p21 pathway, and thus are therapeutic targets for disorders associated with defective p21 function. Methods for identifying modulators of p21, comprising screening for agents that modulate the activity of HADH are provided.
    Type: Grant
    Filed: July 10, 2002
    Date of Patent: August 9, 2005
    Assignee: Exelixis, Inc.
    Inventors: Lori Friedman, Gregory D. Plowman, Roel P. Funke, Marcia Belvin, Danxi Li, Stephanie A. Robertson
  • Publication number: 20050170344
    Abstract: Human CHD genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of CHD are provided.
    Type: Application
    Filed: June 3, 2002
    Publication date: August 4, 2005
    Inventors: Lori Friedman, Gregory Plowman, Marcia Belvin, Helen Francis-Lang, Danxi Li, Roel Funke, Mario Lioubin
  • Patent number: 6924117
    Abstract: Rhomboid Related Proteins (RRPs), involved in the EGFR signaling pathway, are provided. Transgenic, nonhuman mammals containing a transgene encoding an RRP polypeptide or a gene effecting the expression of an RRP polypeptide, along with methods of modulating the interaction of RRP proteins with their pathway members, and methods of screening for agents that modulate the interaction of an RRP polypeptide with an RRP binding target, such as RRP-specific antibodies and small molecules identified in high throughput screens, are also provided. Modulating agents identified using the methods of the invention can be used to specifically inhibit growth of tumor cells that overexpress an RRP protein.
    Type: Grant
    Filed: July 18, 2001
    Date of Patent: August 2, 2005
    Assignee: Exelixis, Inc.
    Inventors: Mario N. Lioubin, Lori Friedman, Marcia Belvin, Jeffery S. Larson, Changyou Chen, Stephanie A. Robertson, Wen Shi, Jocelyn Chan, Danxi Li
  • Publication number: 20050112568
    Abstract: Human DGK genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53,comprising screening for agents that modulate the activity of DKG are provided.
    Type: Application
    Filed: June 3, 2002
    Publication date: May 26, 2005
    Inventors: Lori Friedman, Gregory Plowman, Mercia Belvin, Helen Francis-Lang, Danxi Li, Roel Funke
  • Publication number: 20030165497
    Abstract: RRP genes are identified as modulators of the p53 or p21 pathway, and thus are therapeutic targets for disorders associated with defective p53 or p21 function. Methods for identifying modulators of p53 or p21, comprising screening for agents that modulate the activity of RRP are provided. Modulating agents identified using the methods of the invention can be used to specifically inhibit growth of tumor cells that overexpress an RRP protein. mRRP1 knockout mice are also provided.
    Type: Application
    Filed: January 23, 2002
    Publication date: September 4, 2003
    Inventors: Mario N. Lioubin, Lori Friedman, Marcia Belvin, Jeffrey S. Larson, Changyou Chen, Stephanie A. Robertson, Wen Shi, Jocelyn Chan, Danxi Li, Helen Francis-Lang, Gregory D. Plowman, Roel P. Funke, Michael Schoor, Branko Zevnik, Gunther Kauselmann, Hartmut Tintrup